Effects of antipsychotics on brain structure

Current Opinion in Psychiatry

Volumn 19, Issue 2, 2006, Pages 145-150

  Scherk, Harald ^a   Falkai, Peter ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Antipsychotics; Basal ganglia; Brain structure; Magnetic resonance imaging

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BASAL GANGLION; BRAIN CORTEX; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; FOLLOW UP; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; LONGITUDINAL STUDY; MORPHOMETRICS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PSYCHOPHARMACOLOGY; PSYCHOSIS; PUTAMEN; REVIEW; SCHIZOPHRENIA; THALAMUS; BRAIN; HISTOLOGY; PATHOPHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; BRAIN; CEREBRAL CORTEX; HUMANS; MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA; THALAMUS;

EID: 33646828012     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000214339.06507.d8     Document Type: Review

References (36)

1. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry 1999; 45:1099-1119.
2. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49:1-52.
3. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998; 172:110-120.
4. DeLisi LE, Sakuma M, Tew W, et al. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997; 74:129-140.
5. Lieberman J, Chakos M, Wu H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001; 49:487-499.
6. Ho BC, Andreasen NC, Nopoulos P, et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60:585-594.
7. Woods BT. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 1998; 155:1661-1670.
8. Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res 1999; 40:87-99.
9. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001; 50:729-742.
10. Scherk H, Falkai P. Changes in brain structure caused by neuroleptic medication. Nervenarzt 2004; 75:1112-1117.
11. Bilder RM, Wu H, Chakos MH, et al. Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry 1994; 55 (Suppl B):53-56.
12. Gur RE, Maany V, Mozley PD, et al. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998; 155:1711-1717.
13. Pressler M, Nopoulos P, Ho BC, Andreasen NC. Insular cortex abnormalities in schizophrenia: relationship to symptoms and typical neuroleptic exposure. Biol Psychiatry 2005; 57:394-398. This is the first study examining the effect of antipsychotic treatment on insular cortex.
14. Dazzan P, Morgan KD, Orr K, et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005; 30:765-774. In this study, the increased thalamic volume was positively associated with dose of olanzapine.
15. Scheepers FE, Gispen de Wied CC, Hulshoff Pol HE, Kahn RS. Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. Am J Psychiatry 2001; 158:644-646.
16. Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999; 156:1200-1204.
17. Lang DJ, Kopala LC, Vandorpe RA, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 2004; 161:1829-1836.
18. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62:361-370. Owing to a large number of subjects and long-term examination, this is a very important study. Treatment with haloperidol lead to a decrease in grey matter volume and an increase in caudate volume.
19. Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151:1430-1436.
20. Keshavan MS, Bagwell WW, Haas GL, et al. Changes in caudate volume with neuroleptic treatment. Lancet 1994; 344:1434.
21. Lang DJ, Kopala LC, Vandorpe RA, et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry 2001; 158:625-631.
22. Heitmiller DR, Nopoulos PC, Andreasen NC. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr Res 2004; 66:137-142.
23. Massana G, Salgado-Pineda P, Junque C, et al. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J Clin Psychopharmacol 2005; 25:111-117. In contrast to other findings, these authors observed an increased grey matter volume of caudate after exposition to risperidone.
24. Tauscher-Wisniewski S, Tauscher J, Christensen BK, et al. Volumetric MRI measurement of caudate nuclei in antipsychotic-naive patients suffering from a first episode of psychosis. J Psychiatr Res 2005; 39:365-370. These authors could not observe effects of quetiapine on brain structure in neuroleptic-naïve patients.
25. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry 2005; 58:62-66. This VBM examination revealed increased cortical grey matter volume following atypical but not typical treatment.
26. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry 2002; 59:553-558.
27. Miller DD, Andreasen NC, O'Leary DS, et al. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology 1997; 17:230-240.
28. Chakos MH, Shirakawa O, Lieberman J, et al. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 1998; 44:675-684.
29. Benes FM, Paskevich PA, Davidson J, Domesick VB. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res 1985; 329:265-273.
30. Falkai P, Tepest R, Schulze TG, et al. Etiopathogenetic mechanisms in long-term course of schizophrenia. Pharmacopsychiatry 2004; 37 (Suppl 2):S136-S140.
31. Cosi C, Waget A, Rollet K, et al. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 2005; 1043:32-41.
32. Millan MJ. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 2005; 179:30-53.
33. Fumagalli F, Molteni R, Bedogni F, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 2004; 15:2109-2112.
34. Angelucci F, Aloe L, Iannitelli A, et al. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005; 15:311-317.
35. Halim ND, Weickert CS, McClintock BW, et al. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004; 29:1063-1069.
36. Wang HD, Dunnavant FD, Jarman T, Deutch AY. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004; 29:1230-1238.